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Summary
Objectives: To investigate the secretion profiles of matrix metalloproteinases (MMP) and their inhibitors (TIMP) in synovial fluid-derived
fibroblasts and to compare them with those of tissue-derived fibroblasts.
Methods: Fibroblast cultures established from synovial tissues (TSC) and fluids (FSC) of the same OA patients were stimulated with tumor
necrosis factor(TNF)-, interleukin(IL)-1, IL-1, IL-6 and a combination of TNF and IL-1. Cocultures of fibroblasts and cartilage were
stimulated either with the cytokine combination or with osteoarthritic synovial fluid. Secretion of MMP-1, MMP-3, MMP-8, MMP-13, TIMP-1,
and TIMP-2 was measured by enzyme-linked immunosorbent assay. Gelatin zymography and immunoblotting were performed to
demonstrate enzyme activity.
Results: TNF, IL-1, and IL-1 led to marked increases in MMP-1 and MMP-3 release (up to 4.2-fold and 547-fold, respectively) by synovial
fibroblasts, whereas secretion of MMP-13 was induced by concomitant administration of TNF and IL-1. Expression of intracellular MMP-8
was stimulated by cytokines, but adhesion of synovial fibroblasts to cartilage was required for the release. Throughout the study, significantly
higher levels of secreted MMPs were observed in stimulated FSC compared to TSC cultures. Furthermore, increases in MMP secretion were
not accompanied by increases in secreted TIMP-1 and TIMP-2, resulting in marked imbalances between enzyme and inhibitor levels.
Conclusions: The results provide strong evidence for a significant impact of synovial-derived MMPs on cartilage destruction in OA. In this
context, fibroblasts present in the synovial fluid appeared to play an outstanding role.
© 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
Key words: Osteoarthritis, MMP, Cytokine, Synovial fibroblast.
Introduction
Osteoarthritis (OA) is a joint disease characterized by the
degeneration of articular cartilage and weakening of the
subchondral bone. Although OA is defined as a non-
inflammatory arthropathy, inflammatory changes of the
synovial membrane have been described, and excessive
production of proinflammatory cytokines by the inflamed
synovium, activated chondrocytes, and infiltrated inflamma-
tory cells have been implicated as an important mediator of
disease progression in OA1,2. In particular, interleukin-1
(IL-1) and tumor necrosis factor (TNF)-alpha have been
demonstrated to be predominantly involved in the initiation
and progression of articular cartilage destruction. The
ability of IL-1 and TNF to promote cartilage degradation is
linked to their ability to promote the synthesis and release
of matrix-degading proteases and to suppress proteogly-
can and collagen synthesis by human chondrocytes and
synovial cells3–5. Several studies implicated a major role for
aggrecanases6,7 and matrix metalloproteinases (MMP) in
the degradation process of articular cartilage8–10. Among
the last-mentioned, the collagenase subfamily including
fibroblast collagenase (MMP-1), neutrophil collagenase
(MMP-8), and collagenase 3 (MMP-13) as well as
stromelysin-1 (MMP-3) have been demonstrated to play a
pivotal role in osteoarthritic cartilage destruction11–15.
Regulation of these proteases has been demonstrated not
only by proinflammatory cytokines, but also by activation of
their precurser forms (proMMP). In this context, MMP-3 is
considered to play a central role in the activation of various
pro-MMPs including pro-MMP-1, pro-MMP-8, pro-MMP-9,
and pro-MMP-1316–18. Moreover, protease activity is strictly
regulated by their natural inhibitors, named tissue inhibitors
of matrix metalloproteinases (TIMP)19 and an imbalance
between MMPs and TIMPs is supposed to favor exessive
degradation of articular cartilage in OA20,21.
MMP-1, MMP-3, and MMP-13 have shown to be present
in osteoarthritic synovial fluid and elevated levels have
been reported for MMP-1 and MMP-3, but the exact source
of the degradative enzymes remains difficult to define22–24.
Three lines of evidence suggest an important role of
synovial enzymes in the pathophysiology of OA. First,
synovial expression of MMP-1, MMP-3, MMP-8, and
MMP-13 has been described in OA25–32. Second, invasion
of synovial fibroblasts is an important feature of carti-
lage degradation and invasiveness correlates with the
expression of specific MMP transcripts32,33. Finally,
adhesion of cytokine-activated synovial fibroblasts to the
cartilage matrix via the hyaluronan receptor (CD44)
induces cartilage degradation in vitro34,35. Although a major
impact of synovial fibroblasts is strongly implicated, the
association of joint inflammation with the release and
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activity of synovial MMPs has not been clearly established
in OA. Moreover, the existence of synovial fibroblasts
that can be obtained from synovial fluid of patients with
OA raises the question whether these cells, in addition
to synovial tissue fibroblasts, may be involved in the
destructive process in OA.
In order to explore the cartilage-degrading potential of
fluid-derived fibroblasts, we analysed the secretion of
MMP-1, MMP-3, MMP-8, MMP-13, TIMP-1, and TIMP-2
under inflammatory conditions and investigated whether
these cells exhibit similar secretion profiles than tissue-
derived fibroblasts.
Patients and methods
PATIENTS
Synovial membrane tissues and fluids were obtained
from 6 OA patients undergoing implant surgery for total
knee replacement. All membrane specimens were taken
from the recessus superior of the knee. The mean age of
patients was 67 years (range 60–73 years), and the ratio of
men to women was 1:2. All patients had grade 4 knee OA
according to the Kellgren and Lawrence criteria, based on
weight-bearing radiographs36. No steroid or HA intra-
articular injection had been administered for the previous 2
months before the study. Except one, none of patients
routinely used any drugs with known potential for altering
synovial cell metabolism, such as nonsteroidal anti-
inflammatory drugs. One patient received prednisolone
(5 mg/day) because of renal transplantation. All patients
gave signed consent prior to the surgery.
CELL ISOLATION AND CULTURE CONDITIONS
Synovial fibroblast cultures were established from syno-
vial tissue and synovial fluid of each patient. Specimens
were cut into small pieces and dissociated enzy-
matically with a trypsin/EDTA solution (0.05%/0.02%, PAA
Laboratories, Coelbe, Germany) for 1 h at 37°C. Digested
tissues were pipetted through a 200-µm nylon mesh, spun
down, and cells were washed twice with phosphate-
buffered saline (PBS). Isolation of synovial fibroblasts from
fluid samples was performed by dilution of fluids 1 to 4 with
PBS and subsequent centrifugation. Isolated cells were
cultured in Dulbecco’s modified Eagle’s medium (DMEM)
with high glucose (Gibco-BRL, Eggenstein, Germany) sup-
plemented with 10% heat-inactivated fetal calf serum (FCS;
Gibco-BRL) at 37°C and 5% CO2 in 75-cm2 flasks. All
culture media were supplemented with 100 U/ml penicillin
G, 100 µg/ml streptomycin and 250 µg/ml amphotericin C
(Gibco-BRL). Non-adherent cells were removed by the
replacement of culture medium at 4 to 6 day intervals.
Usually after 2 to 4 weeks both membrane and fluid cell
preparations had developed a confluent uniform mono-
layer of fibroblast-like nature with microscopically no
morphological differences.
STIMULATION OF SYNOVIAL FIBROBLASTS
For stimulation experiments, synovial membrane and
fluid fibroblasts in passage 3 were grown in 24-well plates.
To avoid detachment of the adherent cells, sometimes
observed at fully confluence, or even stress to the cells
during the stimulation period, fibroblasts were used at
semi-confluence. Prior to stimulation, cells were washed
and starved for 24 h in DMEM containing 5% FCS followed
by a 24 h-incubation in DMEM supplemented with 0.2%
FCS. Both tissue and fluid synovial fibroblasts of the
individual patients were incubated in triplicates with the
following cytokines at final concentrations of 10 ng/ml:
human recombinant TNF, IL-1, IL-1, IL-6, and a combi-
nation of IL-1 and TNF. Specificity of stimulation was
determined by inhibition experiments using monoclonal
anti-human TNF antibodies (working concentration
50 µg/ml) and recombinant human IL-1 receptor antagonist
(IL-1Ra; working concentration 500 ng/ml). All cytokines
were purchased from R&D Systems, Nordenstadt,
Germany. After 48 hours of stimulation, supernatants were
harvested, centrifuged, and frozen at minus 80°C until
analyzed.
COCULTURE EXPERIMENTS
Normal cartilage was dissected on the day of slaughter
from bovine metacarpophalangeal joints, sliced in small
pieces (2–4 mm), and washed several times with PBS.
Cartilage was devitalized by four cycles of freezing at
minus 80°C overnight and thawing, to avoid para-
crine effects of chondrocyte-derived soluble factors. For
adhesion experiments, identical amounts of cartilage slices
were applied to the bottom of 24-well plates and overlayed
with 800 µl DMEM/0.2% FCS. After 24 h the medium was
refreshed and 200 µl medium containing 1×105 synovial
fibroblasts were added either directly to the cartilage discs
or in transwell tissue culture inserts (Becton Dickinson,
Heidelberg, Germany). These inserts with a porus size of
0.4 µm allow diffusion of soluble factors, but prevent con-
tact between cartilage and synovial fibroblasts. After an
initial culture period of 3 days, the medium was refreshed
and both coculture settings as well as their corresponding
monocultures were incubated with 10 ng/ml TNF/IL-1 or
osteoarthritic synovial fluid for 72 h. Synovial fluids were
exclusively obtained from patients with high-grade osteo-
arthritis (N=5), assuming that they were all stimulatory. To
get more representative results, the frozen cell-free fluids
were pooled and diluted 1:1 with DMEM/0.2% FCS prior to
stimulation.
PREPARATION OF CELL EXTRACTS
Extracts from synovial fibroblasts were generated by
lysis of cells at 4°C using a Triton-based extraction buffer
(100 mM Tris-HCl, pH 8.0; 0.5% Triton X-100; 10 mM
EDTA). Total protein was extracted by repeated freeze and
thaw cycles, followed by centrifugation for 5 min at
15,000 rpm at 4°C. Supernatants were collected, frozen in
liquid nitrogen, and stored at minus 80°C until analysis.
Total protein content of the cell extracts were determined by
the Bradford method37.
ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA)
Production and secretion of total MMP-1, MMP-8, MMP-
13, MMP-3, TIMP-1, and TIMP-2 were measured in culture
supernatants or cell extracts (MMP-8) by standard sand-
wich ELISA technique (Amersham Pharmacia Biotech,
Buckinghamshire, UK). The individual steps were per-
formed according to the manufacturer’s instructions. All
MMP-ELISA detected total MMPs, including pro- and active
forms as well as MMPs complexed to TIMPs. The lower
detection limits of the assays for MMP-1, -3, -8, and -13
were 1.7 ng/ml, 2.35 ng/ml, 0.032 ng/ml, and 0.032 ng/ml,
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respectively. The assays for TIMP-1 and -2 detected the
free forms and those complexed to MMPs with sensitivities
of 1.25 ng/ml and 3.0 ng/ml, respectively. Concentrations
of MMPs and TIMPs are presented as ng/ml or pg/ml
corrected for 105 cells.
GELATIN-ZYMOGRAPHY
Culture supernatants were mixed with four-fold concen-
trated sample loading buffer (4 mM EDTA, 4% SDS, 40%
glycerol, 0.04% bromophenol blue, 40 mM Tris/HCl,
pH 6.8) and subjected to electrophoresis on a 0.1% gelatin-
containing 10% SDS-polyacrylamide gel. Protein standards
within the range of 180 kDa to 26 kDa were used as
molecular weight markers (Sigma, Taufkirchen, Germany).
The gels were washed twice for 30 min in 2.5% Triton-X
100, rinsed in distilled water, and developed for 16 h at
37°C in 50 mM Tris/HCl pH 8.5 containing 5 mM CaCl2.
Finally, gels were stained with Coomassie brilliant
blue R250 (Serva, Heidelberg, Germany) to visualize
protease activity and analyzed using a gel analysis
and documentation system (Gel Doc 1000; Bio-Rad
Laboratories).
IMMUNOBLOTTING
TCA-precipitated medium samples and protein stan-
dards (Sigma) were subjected to electrophoresis on 10%
SDS-polyacrylamide gels. Proteins were then electro-
transferred at a constant current of 2 mA/cm2 to nitro-
cellulose membranes for 2 h. The membranes were
blocked with 5% dried milk in TBS-T (20 mM Tris/HCl,
137 mM sodium chloride, 0.02% Tween-20) at RT for 2 h
and incubated with polyclonal rabbit antibodies against
human MMP-1, MMP-3, MMP-8, and MMP-13 (Chemicon
International, Hofheim, Germany; diluted as recommended
by the manufacturer) in TBS-T/ 3% bovine serum albumine
(BSA; Sigma) supplemented with 0.05% NaN3 at 4°C
overnight. Membranes were washed six times with TBS-T
and incubated for 2 h at RT with goat anti-rabbit
horseradish peroxidase-conjugated antibodies (DAKO
Diagnostica, Hamburg, Germany), diluted 1:1000 in TBS-
T/5% dried milk. Detection of MMPs was performed using
the enhanced chemiluminescence method (Amersham
Pharmacia Biotech, Buckinghamshire, UK).
STATISTICAL ANALYSIS
Data are presented as medians and interquartile ranges
(IQRs). Statistical significance of overall differences
between multiple groups was analyzed by the Kruskal-
Wallis one-way analysis of variance. If the test was
significant, pairwise comparisons were done by the
multiple-comparisons‘ criterion. Differences between two
independent groups were analyzed by the Mann-Whitney
rank sum test. A P-value of 0.05 or less was considered
significant.
Results
CYTOKINE-STIMULATED SECRETION OF MMPS BY SYNOVIAL
FIBROBLASTS
All cytokines induced an overall increase in MMP-1
secretion up to 3.3-fold in TSC and 4.2-fold in FSC
(P<0.001 for overall group differences) (Fig. 1). Cytokine-
mediated increases of MMP-1 levels in culture super-
natants were significantly higher in FSC than in TSC
(P<0.002 for TNF and IL-1, P<0.005 for IL-1, P<0.03 for
TNF/IL-1, and P<0.05 for IL-6; Mann–Whitney test).
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Fig. 1. Effects of cytokines on MMP-1 secretion by synovial fibroblasts. TSC (A) and FSC (B) were incubated with or without various
recombinant cytokines at concentrations of 10 ng/ml. Total MMP-1 concentrations were determined in culture supernatants after 48 h. Data
represent median values and IQRs of stimulation experiments of 6 independent cultures each. Analysis of significance for overall group
differences was performed by the Kruskal–Wallis test (P<0.001). The multiple comparisons‘ criterion was employed to identify differences
between the groups (IL-1 and IL-1 vs controls, P<0.05; TNF/IL-1 vs controls, P<0.001; TNF/IL-1 vs IL-6, P<0.05 for both TSC and
FSC).
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Similar to MMP-1 but more efficiently, cytokine stimulation
led to increased MMP-3 secretion by TSC (36- to 194-fold)
and FSC (25- to 547-fold) (P<0.002 and P<0.001, repec-
tively, for overall group differences). Comparisons between
TSC and FSC revealed similar basal MMP-3 levels,
whereas significant higher levels were observed in the FSC
cultures after stimulation with TNF, IL-1, and IL-1
(P<0.002). The cytokine combination showed synergistic
effects on MMP-3 secretion with more than 5-fold higher
levels in FSC than in TSC (median 2450 ng/ml; IQR, 1381
to 2949 ng/ml vs 13310 ng/ml; IQR, 10790 to 20206 ng/ml;
P<0.001; Mann–Whitney test) (Fig. 2). In opposition to
MMP-1 and MMP-3, unstimulated synovial fibroblast cul-
tures showed no secretion of MMP-13. Additionally,
secretion of MMP-13 by TSC was only induced by con-
comitant administration of TNF and IL-1, whereas
secretion by FSC was stimulated by the cytokines IL-1,
IL-1, and the cytokine combination, but not by TNF alone
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Fig. 2. Effects of cytokines on MMP-3 secretion by synovial fibroblasts. TSC (A) and FSC (B) were incubated with or without various
recombinant cytokines at concentrations of 10 ng/ml. Total MMP-3 concentrations in culture supernatants after 48 h are presented as median
values and IQRs of 6 independent cultures each. Analysis of significance for overall group differences was performed by the Kruskal–Wallis
test (P<0.001). The multiple comparisons‘ criterion was employed to identify differences between groups (TSC: TNF/IL-1 vs controls,
P<0.01; FSC: IL-1, IL-1 vs controls, P<0.05; TNF/IL-1 vs controls, P<0.005; TNF/IL-1 vs IL-6, P<0.01).
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Fig. 3. Effects of cytokines on MMP-13 secretion by synovial fibroblasts. TSC (A) and FSC (B) were incubated with or without various
recombinant cytokines at concentrations of 10 ng/ml. Total MMP-13 concentrations in culture supernatants after 48 h are presented as
median values and IQRs of six independent cultures each. Stars indicate the absence of detectable protein. Analysis of significance for
overall group differences was performed by the Kruskal–Wallis test (P<0.001). The multiple comparisons‘ criterion revealed differences
between groups solely in FSC (TNF/IL-1 vs controls, TNF, and IL-6, P=0.01).
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or IL-6 (P<0.0001 for overall group differences)(Fig. 3).
Similar to MMP-1 and MMP-3, levels of MMP-13 were
significantly higher in FSC than in TSC after exposure to
the cytokine combination (6.8-fold; P<0.02; Mann–Whitney
test).
In opposition to the other MMPs, analysis of culture
supernatants revealed no evidence for basal or cytokine-
induced MMP-8 secretion in any of the cell cultures tested.
Interestingly, levels of intracellular MMP-8 did not reflect
the lack of MMP-8 secretion. Although basal intracellular
MMP-8 was detectable in only 50% of the TSC and FSC
cultures, production of MMP-8 was induced and/or upregu-
lated upon cytokine stimulation in both cell preparations
(Fig. 4). However, no significant differences in intracellular
MMP-8 levels were found between TSC and FSC (Mann–
Whitney test).
INDUCTION OF MMP-8 SECRETION BY SYNOVIAL FIBROBLASTS
In a subsequent series of coculture experiments, we
determined whether secretion of intracellular MMP-8
requires contact between synovial fibroblasts and cartilage.
For this purpose, TSC and FSC were cultured with bovine
cartilage discs either directly or separately, using transwell
tissue culture inserts. Consistent with the results of the
monocultures, no release of MMP-8 into the culture super-
natants was evident in the transwell cocultures after stimu-
lation with the cytokine combination. In contrast, direct
contact of these cells to the cartilage discs led to secretion
of MMP-8 (Fig. 5A). The unexpectedly low enzyme
levels prompted us to further investigate whether soluble
factors, provided by the synovial fluid, could trigger MMP-8
secretion. For this purpose, both adherence and transwell
cocultures were stimulated with synovial fluid of osteo-
arthritic patients. Again, no MMP-8 secretion was detect-
able in supernatants from transwell cocultures, but the
adhesion-induced secretion of MMP-8 by TSC and FSC
was about 38.9-fold and 63.7-fold higher, respectively,
compared to effects observed by the recombinant cyto-
kines (P<0.05; Mann–Whitney test). Notably, MMP-8 levels
tended to be higher in FSC than in TSC cultures (Fig. 5B).
Simultaneously stimulated monocultures of cartilage and
synovial fibroblasts showed no enzyme secretion.
EFFECTS OF CYTOKINES ON TIMP-1 AND -2 SECRETION BY
SYNOVIAL FIBROBLASTS
Concentrations of TIMP-1 were high in all culture super-
natants, but none of the tested cytokines led to significantly
increased inhibitor levels (median range 3217 ng/ml to
4528 ng/ml for TSC and 2727 ng/ml to 3477 ng/ml for
FSC). Likewise, no cytokine-mediated regulation of TIMP-2
secretion was observed, although concentrations were
consistently low (median range 9.9 ng/ml to 15.9 ng/ml for
TSC and 15.2 ng/ml to 18.1 ng/ml for FSC). Additionally, no
significant differences in TIMP-1 and -2 concentrations
between TSC and FSC were observed (Mann–Whitney
test). The fact that increases in MMP secretion were not
accompanied by increases in the amount of secreted
TIMP-1 and TIMP-2, resulted in changes of the TIMP/MMP
ratios. For example, the TIMP-1/MMP-3 ratio of 226.3
(TSC) and 157.7 (FSC) in unstimulated cells shifted to 1.2
and 0.4, respectively, in TNF/IL-1-stimulated cells.
PROTEOLYTIC ACTIVITIES OF SECRETED MMPS
Gelatin-zymography demonstrated a cytokine-mediated
overall increase of proteolytic activity in both fibroblast
groups of all patients (a representative gel is shown in
Fig. 6). TSC and FSC showed an increase in proteolytic
activity at approximately 50 to 60 kDA, probably corre-
sponding to the proforms of MMP-1 and MMP-3. The
appearance of additional bands between 35 kDa and
50 kDa indicated the presence of additional proteolytic
species or further processed active forms. Among these,
two of them are likely to be the active forms of MMP-1 and
MMP-3. An additional band of gelatinolytic activity was
observed migrating at approximately 62 kDA, probably cor-
responding to the active form of gelatinase A (MMP-2).
However, the almost identical gelatinolytic activity indicated
Fig. 4. Intracellular production of MMP-8 in synovial fibroblasts. Levels of MMP-8 were measured in cell extracts of TSC (open bars) and FSC
(hatched bars) after stimulation with 10 ng/ml of various cytokines for 48 h. Data represent median values and IQRs of stimulation
experiments using four independent cell cultures each (P<0.04 for overall group differences only in TSC, Kruskal–Wallis test). The multiple
comparisons‘ criterion revealed differences between IL-1 and TNF/IL-1 vs controls (P<0.05 and P<0.01, respectively).
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no regulation of this MMP by exogenous cytokines.
Notably, cytokine-induced proteolytic activities in super-
natants of FSC were considerably higher than in those
harvested from TSC.
While zymography demonstrates potential activity, it
does not allow for accurate identification of MMPs possess-
ing nearly similar molecular weights. In addition, some of
the bands may represent proforms of the enzymes that are
activated artificially by the zymography process. In order to
confirm the zymography results and to further analyze
whether pro- and/or active MMP forms were secreted upon
stimulation, immunoblotting of conditioned media from FSC
was performed.
Antibodies to MMP-1 recognized two bands at 53
and 51 kDa, representing the unglycosylated and the
gylycosylated proform of this enzyme, respectively (Fig.
7A). All cytokines, except IL-6, induced a marked increase
in proMMP-1 levels, whereas no active forms with apparent
molecular masses of 44 and 42 kDa were detectable.
Because activated MMP-1 molecules undergo further
autoproteolysis, the appearance of bands at 33 and
28 kDa may indicate the presence of activated enzyme.
Active MMP-1 was probably further processed by dis-
sociation of the catalytic and the hemopexin-like domain
with molecular masses of 33 and 28 kDa, respectively.
Similar to MMP-1, both forms of MMP-3 were highly
induced by the cytokines TNF, IL-1, IL-1, and
the cytokine combination as demonstrated by increased
immunoreactivity of bands migrating at approximately
57 kDa (pro), 45 kDa (active), and 43 kDa (active). In
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Fig. 5. Induction of MMP-8 secretion. TSC and FSC were cultured with bovine cartilage discs either directly (adherence) or separately using
transwell tissue culture inserts (transwell). Enzyme concentrations were determined in coculture supernatants after stimulation with the
cytokine combination TNF/IL-1 (A) or osteoarthritic synovial fluid (1:1 dilution with medium) (B) for 72 h. Data are presented as median
values and IQRs of three independent cell cultures each. Concentrations given in panel B are normalized against synovial fluid
concentrations of MMP-8. Stars indicate the absence of detectable protein.
Fig. 6. Gelatin-zymography of CM derived from stimulated synovial fibroblasts. TSC and FSC were stimulated with 10 ng/ml TNF (lane 2),
IL-1 (lane 3), IL-6 (lane 4), IL-1 (lane 5), and TNF/IL-1 (lane 6) for 48 h. Culture media (CM) from unstimulated control cultures
(lane 1). The representative gel demonstrates increased gelatinolytic activity upon cytokine stimulation, a trend that was apparent in all other
patients tested. Notably, a higher activity was evident in stimulated FSC compared to TSC. Equal loading was confirmed by similar intensities
of lytic bands representing MMP-2.
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contrast, IL-6 failed to induce detectable amounts of
MMP-3 (Fig. 7B).
In contrast to results obtained by ELISA, no cytokine-
induced secretion of MMP-8 and MMP-13 was detectable
by immunoblotting. The inconsistence of the results could
be explained by the different sensitivities of the two
methods. Usually, a concentration of at least 5 to 10 ng of
specific antigen is necessary for successful protein detec-
tion by immunoblotting. Although the conditioned media
were concentrated by TCA precipitation, levels of MMP-8
and MMP-13 remained below the detection limit of the
method.
Discussion
It has recently been shown that synovial fibroblasts
activated by inflammatory cytokines are capable of degrad-
ing cartilage matrix components34,35. Although, inflamma-
tion of the synovium is often observed in OA, even in early
stages of the disease2,38, the association of synovial
inflammation with the release and activity of synovial
MMPs has not been clearly established. Furthermore, no
information is available on the destructive potential of
fibroblasts, that can be obtained from the synovial fluid of
OA patients.
In the present study we demonstrated that both tissue
and fluid synovial fibroblasts secrete MMPs, known to be
important in the process of cartilage destruction. We found
consistent secretion of MMP-3 in all synovial fibroblast
cultures with enormously increased levels upon cytokine
stimulation. The considerable high amounts of secreted
MMP-3 point to the inflamed synovium as a major source of
this protease, presumably responsible for the elevated
MMP-3 levels observed in OA synovial fluids22,24. This
would be in line with recent reports on early upregulation of
MMP-3 in synovia of experimental osteoarthritis39 and on
elevated levels of MMP-3 in synovial membranes of OA
patients compared to normals40. Although the major pro-
portion of the in vitro secreted MMP-3 was the proenzyme,
it is most likely that in vivo the proform is activated by
chondrocyte-derived peptidases41, such as cathepsin B,
the major active cysteine peptidase in OA cartilage42,43.
Thus it could be expected that synovial-derived MMP-3
plays an important role in cartilage degradation either
directly by removel of proteoglycans from the cartilage
matrix44 or indirectly by activation of other members of the
MMP family16–18.
Although MMP-3 can degrade various collagens, it is not
capable of cleaving the intact triple helix of collagen type II,
the major structural protein of cartilage. Among all known
MMPs, the collagenases MMP-1, MMP-8, and MMP-13 are
the only secreted enzymes with type II collagen-degrading
properties. In our study, MMP-1 was consistently secreted
by synovial fibroblasts and cytokine-mediated increases
were observed. The presence of further processed active
forms indicated the secretion of collagenolytic activity. In
contrast to MMP-3 and MMP-1, no basal release of
MMP-13 was evident in any of the cultures, but secretion
could be induced by stimulation with the combination of
TNF and IL-1. Since both cytokines are co-expressed in
the synovial fluid of OA patients, it is likely that under in vivo
conditions MMP-13 is released by the synovial fibro-
blasts45. In comparison to MMP-1, secretion rates of
MMP-13 appeared to be low, but MMP-13 has a 10-fold
greater catalytic activity towards type II collagen compared
to MMP-146, suggesting that already small quantities of
activated synovial MMP-13 may have significant impact on
cartilage degradation.
Fig. 7. Immunoblotting of CM derived from stimulated synovial fibroblasts. FSC were stimulated with 10 ng/ml TNF (lane 2), IL-1 (lane 3),
IL-6 (lane 4), IL-1 (lane 5), and TNF/IL-1 (lane 6) for 48 h. CM from unstimulated control cultures (lane 1). Specific antibodies recognizing
pro- and active forms of MMP-1 (A) and MMP-3 (B) were employed. Analysis revealed a marked increase in MMP-1 as well as MMP-3
secretion upon stimulation with all cytokines, except IL-6. In addition to their proforms, antibodies detected active forms of MMP-3 (*) and
further processed active forms of MMP-1 (#).
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In contrast to MMP-1 and MMP-13, only minimal infor-
mation is available on the involvement of MMP-8 in carti-
lage matrix degradation. Three lines of evidence suggest a
crucial role of MMP-8 in cartilage degradation. First, among
all secreted collagenases, MMP-8 has the highest activity
towards cartilage collagen type II47. Second, MMP-8
uniquely exerts ‘aggrecanase activity’ characterized by
cleavage of aggrecan at the aggrecanase site48,49. Third,
the anti-arthritic effects of tetracyclines are thought to be
due at least in part to the inhibition of MMP-850,51.
Contrarily to a recent study on patients with rheumatoid
arthritis (RA), we observed that in osteoarthritic synovial
fibroblasts exclusively the production of MMP-8 but not the
release is stimulated by inflammatory cytokines, indicating
that MMP-8 secretion is differentially regulated in RA and
OA synovial fibroblasts51. But most importantly, we demon-
strated that secretion of MMP-8 is induced by adhesion of
stimulated synovial fibroblasts to the cartilage matrix and
that adhesion-induced secretion could be further enhanced
by factors within the osteoarthritic synovial fluid. The
exigence of a direct contact between cytokine-activated
fibroblasts and cartilage for the secretion of MMP-8 indi-
cates that, beside inflammatory cytokines, adhesion may
be an important additional regulator of MMP secretion. This
would be in line with recently described stimulatory effects
on MMP-2 secretion by binding of hyaluronan to its recep-
tor (CD44) in lung carcinoma cells52. Moreover, assuming
that direct contact between synovial fibroblasts and the
cartilage matrix is essential for cartilage degradation, it is
tempting to speculate that the induction of MMP-8 secretion
may be a crucial step for fibroblast invasion and fibroblast-
mediated cartilage matrix decomposition, not only for its
collagenolytic activity, but also for its ability to degrade
aggrecan. Furthermore, our observation that adhesion-
induced MMP-8 secretion was highly enhanced by osteo-
arthritic synovial fluid points to additional regulatory
functions of fluid-derived soluble factors in vivo. However,
the differential induction and stimulation of MMP secretion
point to a complex regulatory machinery, including
the cooperation of cytokines, adhesion molecules, and
probably unknown soluble factors within the synovial fluid.
Several studies have suggested that an over-expression
of MMPs relative to TIMPs in OA joints contribute to
cartilage degradation20,21. Indeed, measurements of
MMP-1, MMP-3, MMP-13, and TIMP in synovial fluid
samples of OA patients revealed elevated concentrations
of MMPs relative to TIMP22. The unaltered levels of TIMP-1
and TIMP-2 in both synovial cell culture groups after
cytokine stimulation indicate that the increase in MMP
secretion by TSC and FSC is not compensated sufficiently
by an increase in inhibitor production. This lends further
weight to the argument that synovial MMPs may be impli-
cated in cartilage destruction because the cytokine-
mediated marked imbalance in the inhibitor: enzyme ratio
would highly favour cartilage matrix degradation. The more
pronounced imbalance in the FSC group compared to the
TSC group again supports a major role of fluid synovial
fibroblasts. Nevertheless, it is difficult to define the
functional role of inhibitor levels because it should be
considered that MMP activity is additionally regulated by
cartilage-derived inhibitors. Moreover, cartilage degrada-
tion is likely to be provoked by a cooperation of the activity
of several MMPs provided by both cartilage and synovial
cells.
Our finding that fibroblasts obtained from both synovial
fluid and tissue have the potential to degrade cartilage
matrix components provides strong evidence for a major
impact of synovial MMPs in the pathophysiology of OA.
Moreover, the significant higher release of MMPs by fluid
fibroblasts in combination with their ‘floating’ properties,
which may result in the formation of a multitude of invasion
sites, point to an outstanding role of these cells in cartilage
destruction. Nevertheless, a better understanding of the
release and activity of MMPs as well as their regulation is of
pivotal importance and will help to more accurately identify
effective therapeutic targets for the treatment of OA.
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